肠道微生物群及其代谢物:对于炎症性肠病的新疗法点
Xingyu Shen1,2, Yue Li1,2, Deqiang Wang3
1Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
肠道微生物群失调影响炎症性肠道疾病 (IBD) 的进展. 针对微生物代谢物,如短链脂肪酸 (SCFA),为IBD管理提供了新的治疗策略.
科学领域:
- 胃肠道学和微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD) 的发病过程涉及肠道微生物群失调和改变的代谢物概况.
- 目前IBD治疗的重点是症状管理,缺乏治愈干预措施.
研究的目的:
- 审查IBD诊断和治疗范式.
- 阐明肠道微生物群失调和IBD之间的机制联系.
- 评估用于IBD管理的针对微生物群的治疗方法.
主要方法:
- 关于IBD病变发生,微生物群失调和代谢物功能的文献综述.
- 微生物代谢物 (SCFA,BA,Trp) 的免疫调节作用的分析.
- 评估新兴的针对微生物群的治疗方法 (益生菌,FMT,代谢物干预).
主要成果:
- 肠道微生物群的失调显著影响IBD的进展.
- 微生物代谢物 (SCFA,BA,Trp) 调节肠道免疫和屏障功能.
- 益生菌,FMT和以代谢物为基础的干预措施对IBD治疗有希望.
结论:
- 了解微生物群-代谢物相互作用对于IBD的发病过程至关重要.
- 针对微生物群的治疗方法代表了IBD管理的新途径.
- 进一步的研究可以加速这些有前途的策略的临床转化.
更多相关视频
07:15An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
08:24Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Bacterial Flora of the Large Intestine
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
